Biodesix(US:BDSX) Globenewswire·2026-02-26 21:01Core Insights - Biodesix, Inc. reported a significant revenue growth of 41% in Q4 2025, achieving $28.8 million in revenue and an 83% gross margin, marking a strong performance in the diagnostic solutions sector [1][2] - The company improved its net loss by 52% year-over-year, reaching $4.0 million in Q4 2025, and for the first time, achieved positive Adjusted EBITDA of $0.5 million [1][5] - For FY2026, Biodesix anticipates total revenue between $106-112 million, representing a 23% growth compared to FY2025 [1][7] Financial Performance - Total revenue for FY2025 was $88.5 million, exceeding the guidance of $84-86 million, with a 24% increase from the previous year [4][8] - Diagnostic Tests revenue reached $25.1 million in Q4 2025, a 46% increase year-over-year, driven by a 23% growth in test volume and improved average revenue per test [5][22] - Development Services revenue was $3.6 million in Q4 2025, reflecting a 12% increase year-over-year, contributing to a total of $9.3 million for FY2025, a 41% increase [5][22] Operational Highlights - The gross margin expanded by 400 basis points to 83% in Q4 2025 and by 300 basis points to 81% for FY2025, attributed to increased efficiency in testing workflows and higher average revenue per test [5][6] - Operating expenses for Q4 2025 were $25.8 million, a 14% increase year-over-year, primarily due to investments in sales and marketing to support revenue growth [5][22] - The company reported a significant improvement in Adjusted EBITDA, with a $4.5 million or 113% improvement from Q4 2024, indicating strong operating leverage [5][6] Future Outlook - Biodesix expects continued revenue growth and improvement towards sustained Adjusted EBITDA positivity in FY2026, driven by enhanced sales productivity and additional clinical data on its products [7][8] - The company aims to maintain a gross margin of approximately 80% in FY2026, reflecting its commitment to operational efficiency [8]